Shares of CVS Health (NYSE:CVS) were soaring Wednesday after the diversified healthcare giant's fourth-quarter results topped estimates and management offered better-than-expected guidance for 2025.
As of 11:52 a.m. ET, the stock was up 14.5% on the news.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Image source: Getty Images.
CVS hops over a low bar
CVS, which operates the nation's largest pharmacy chain, health insurer Aetna, and the pharmacy benefit manager Caremark, beat estimates on the top and bottom lines in the fourth quarter. Revenue rose 4.2% to $97.7 billion, compared to the analysts' consensus expectation of $96.9 billion.
Segment-level results were mixed as higher costs due to lost bonus payments from Medicare Advantage plans have weighed on the business. Its medical loss ratio (the percentage of health insurance premiums it pays out as claims) increased from 88.5% to 94.8%, which resulted in an adjusted operating loss of $439 million, down from a $676 million profit in the same quarter a year ago.
Profits were more stable in its two other segments, pharmacy and consumer wellness, but still declined. As a result, adjusted earnings per share declined from $2.12 to $1.19. However, that still topped the consensus estimate of $0.92.
"We have continued to see growth in key areas of our business, including the Pharmacy and Consumer Wellness segment, while we address the industrywide challenges that have impacted our Health Care Benefits segment," said CEO David Joyner, who just completed his first full quarter with the company.
What's next for CVS
In its guidance for 2025, the company forecast that adjusted EPS would rebound to between $5.75 and $6.00, up from $5.42 in 2024, though the midpoint of that range is below the $5.97 analyst consensus.
That guidance indicates that the worst of the headwinds from the changes to Medicare Advantage reimbursements are over, and implies that many of the company's problems are fixable. Based on that guidance, CVS trades at a forward P/E of less than 11, which looks like a good price for an industry leader. If the company can deliver on that guidance, the stock should move higher over the course of the year.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $344,352!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $44,103!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $543,649!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of February 3, 2025
Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)